Drug intelligence / Profile preview

PTx809

Development stage: Preclinical
Lead developer: Primal Therapies
Modality: Small Molecules
Administration: Topical, Buccal

Overview

PTx809 is a preclinical-stage small molecule therapeutic being developed by Primal Therapies for daily oral care. It utilizes the company's proprietary SMMRT (Selective Microbial Metabolism Regulation Technology) platform, which is designed to selectively regulate oral microbial metabolism rather than non-selectively eliminating bacteria. PTx809 is characterized as a prebiotic, postbiotic, and antimicrobial agent that aims to maintain a healthy oral microbiome. The asset is currently in formulation development as a powder intended for out-licensing to commercial partners.

Beyond the preview

Go deeper on PTx809.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTx809.

Explore the full profile